Cyclophosphamide News and Research

RSS

Cyclophosphamide is a drug that is used to treat many types of cancer and is being studied in the treatment of other types of cancer. It is also used to treat some types of kidney disease in children. Cyclophosphamide attaches to DNA in cells and may kill cancer cells. It is a type of alkylating agent. Also called CTX and Cytoxan.

Cyclophosphamide is a synthetic alkylating agent chemically related to the nitrogen mustards with antineoplastic and immunosuppressive activities. In the liver, cyclophosphamide is converted to the active metabolites aldophosphamide and phosphoramide mustard, which bind to DNA, thereby inhibiting DNA replication and initiating cell death.

Probiotics improve ovarian damage in premature menopausal mice

Findings suggest probiotics could mitigate ovarian decline and improve microbiota in POI mice, paving the way for new treatments in women's health.

4 Jul 2025

Partial match stem cell transplants show strong survival rates

Blood cancer patients who may have previously struggled to find a donor for transplantation now have more options.

26 Jun 2025

Mass General Brigham researchers share cancer research discoveries at ASCO 2025

Researchers from Mass General Brigham will present research discoveries and outcomes from clinical trials in cancer at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting, held May 30-June 3, in Chicago.

30 May 2025

Refining the diagnosis of large granular lymphocytic leukemias and their mimics

Large granular lymphocytic leukemias (LGLLs) are a heterogeneous group of rare chronic lymphoproliferative disorders characterized by the clonal proliferation of cytotoxic lymphocytes. Among them, T-cell LGLL (T-LGLL) and NK-cell LGLL (NK-LGLL) are the most prominent.

10 Apr 2025

Metronomic chemotherapy offers hope for children with neuroblastoma

Neuroblastoma is the most common extracranial solid tumor in children, with nearly 50% of cases diagnosed at an advanced stage, often with metastatic disease.

23 Jan 2025

Adjuvant anthracycline- plus taxane-based chemotherapy regimen improves survival in high-risk breast cancer patients

Patients with early-stage, node-negative, hormone receptor (HR)-positive, HER2- negative breast cancer who have a high risk of recurrence based on the OncotypeDX genomic test had better outcomes when treated with adjuvant anthracycline- plus taxane-based chemotherapy regimens compared with those receiving adjuvant taxane-based chemotherapy regimens alone, according to results presented at the San Antonio Breast Cancer Symposium (SABCS), held December 10-13, 2024.

14 Dec 2024

Prostate cancer vaccines: Progress, challenges, and future directions

Prostate cancer vaccines, including dendritic and peptide types, offer hope for improved treatments, but face hurdles in clinical effectiveness and validation.

11 Dec 2024

Novel drug combination shows promise for CLL treatment

A novel, fixed-duration drug combination - consisting of a second-generation BTK inhibitor, called acalabrutinib, plus a BCL-2 inhibitor (venetoclax), with or without a third blood cancer drug - shows deep and durable responses in patients with chronic lymphocytic leukemia (CLL), Dana-Farber Cancer Institute investigator Jennifer Brown, MD, PhD, reports at the 66th American Society for Hematology (ASH) Annual Meeting and Exposition, on behalf of the trial investigators.

9 Dec 2024

Triptolide-based treatment prolongs symptom-free survival in preclinical medulloblastoma models

A drug that was developed to treat pancreatic cancer has now been shown to increase symptom-free survival in preclinical medulloblastoma models – all without showing signs of toxicity.

1 Aug 2024

New curative treatment for sickle cell disease shows promising results in international trial

Vanderbilt University Medical Center (VUMC) researchers are touting data from a multicenter, international phase 2 clinical trial showing a new, curative treatment for sickle cell disease (SCD).

25 Jun 2024

New stem cell transplant approach may expand donor pool for high-risk blood cancer patients

A new treatment approach using an older drug may enable more patients with high-risk blood cancers to receive transplanted stem cells from unrelated, partially matched donors, according to a study conducted by researchers at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine and colleagues.

23 May 2024

Pigeon virus causes fatal neurological disease in young leukemia patient

A case report details a fatal neurologic disease in an immunocompromised toddler caused by pigeon avian paramyxovirus, underscoring the effectiveness of metagenomic testing in diagnosing complex infectious diseases.

19 Nov 2023

Autologous stem cell transplant shows promise for young patients with severe juvenile systemic sclerosis

New research at ACR Convergence 2023, the American College of Rheumatology's (ACR) annual meeting, shows that patients with refractory juvenile systemic sclerosis improved significantly on nearly all measures for two years following autologous stem cell transplant.

10 Nov 2023

Exploring the link between drugs and microbiota: a growing imperative in precision medicine

The intricate interactions between gut microbiota and drugs.

11 Oct 2023

ACT and personalized cancer vaccine combo shows efficacy in ovarian cancer patients

A Ludwig Cancer Research study has shown that combining adoptive T cell therapy (ACT) with an innovative, personalized cancer vaccine under development at the Lausanne Branch of the Ludwig Institute for Cancer Research can benefit patients with late-stage, drug-resistant ovarian cancer.

21 Sep 2023

Subclonal neoantigens present a key roadblock in MMRd tumor immunotherapy success

Researchers evaluated sensitivity to immune checkpoint blockade (ICB) therapy.

20 Sep 2023

New way to administer CAR-T-cell therapy could lead to fewer side effects

When Richard O'Neil, Ph.D., joined MUSC Hollings Cancer Center two years ago, he knew that he wanted to continue finding ways to make CAR-T-cell therapy easier on patients.

8 Sep 2023

New standard more effective at preventing graft-versus-host disease

Clinicians have a new standard for graft-versus-host disease (GVHD) prevention after allogeneic hematopoietic stem cell transplantation, according to results from a phase III study published June 22 in the New England Journal of Medicine.

22 Jun 2023

Phase I clinical study of TCR NK cell therapy for sarcoma expected to commence later this year

The University of Texas MD Anderson Cancer Center and Replay today announced that the Food & Drug Administration (FDA) has issued a 'safe to proceed' for the Investigational New Drug (IND) application for NY-ESO-1 TCR/IL-15 NK, an engineered T cell receptor natural killer (TCR NK) cell therapy for advanced synovial sarcoma and myxoid/round cell liposarcoma.

20 Jun 2023

First-in-human clinical study begins investigating the duoCAR T-cell therapy for treatment of HIV

UC Davis Health researchers have dosed the second participant in their clinical trial looking to identify a potential cure for HIV utilizing CAR T-cell therapy.

19 Apr 2023